Terns Pharmaceuticals Inc
NASDAQ:TERN

Watchlist Manager
Terns Pharmaceuticals Inc Logo
Terns Pharmaceuticals Inc
NASDAQ:TERN
Watchlist
Price: 6.515 USD -3.91%
Market Cap: 549.9m USD
Have any thoughts about
Terns Pharmaceuticals Inc?
Write Note

Intrinsic Value

TERN's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one TERN stock under the Base Case scenario is 3.121 USD. Compared to the current market price of 6.515 USD, Terns Pharmaceuticals Inc is Overvalued by 52%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TERN Intrinsic Value
3.121 USD
Overvaluation 52%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Terns Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for TERN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about TERN?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Pharmaceuticals Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Terns Pharmaceuticals Inc

Provide an overview of the primary business activities
of Terns Pharmaceuticals Inc.

What unique competitive advantages
does Terns Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Terns Pharmaceuticals Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Terns Pharmaceuticals Inc.

Provide P/S
for Terns Pharmaceuticals Inc.

Provide P/E
for Terns Pharmaceuticals Inc.

Provide P/OCF
for Terns Pharmaceuticals Inc.

Provide P/FCFE
for Terns Pharmaceuticals Inc.

Provide P/B
for Terns Pharmaceuticals Inc.

Provide EV/S
for Terns Pharmaceuticals Inc.

Provide EV/GP
for Terns Pharmaceuticals Inc.

Provide EV/EBITDA
for Terns Pharmaceuticals Inc.

Provide EV/EBIT
for Terns Pharmaceuticals Inc.

Provide EV/OCF
for Terns Pharmaceuticals Inc.

Provide EV/FCFF
for Terns Pharmaceuticals Inc.

Provide EV/IC
for Terns Pharmaceuticals Inc.

Show me price targets
for Terns Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Terns Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Terns Pharmaceuticals Inc?

What are the Net Income projections
for Terns Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Terns Pharmaceuticals Inc?

What are the EPS projections
for Terns Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Terns Pharmaceuticals Inc?

What are the EBIT projections
for Terns Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Terns Pharmaceuticals Inc?

Compare the revenue forecasts
for Terns Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Terns Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Terns Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Terns Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Terns Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Terns Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Terns Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Terns Pharmaceuticals Inc.

Provide ROE
for Terns Pharmaceuticals Inc.

Provide ROA
for Terns Pharmaceuticals Inc.

Provide ROIC
for Terns Pharmaceuticals Inc.

Provide ROCE
for Terns Pharmaceuticals Inc.

Provide Gross Margin
for Terns Pharmaceuticals Inc.

Provide Operating Margin
for Terns Pharmaceuticals Inc.

Provide Net Margin
for Terns Pharmaceuticals Inc.

Provide FCF Margin
for Terns Pharmaceuticals Inc.

Show all solvency ratios
for Terns Pharmaceuticals Inc.

Provide D/E Ratio
for Terns Pharmaceuticals Inc.

Provide D/A Ratio
for Terns Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Terns Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Terns Pharmaceuticals Inc.

Provide Quick Ratio
for Terns Pharmaceuticals Inc.

Provide Current Ratio
for Terns Pharmaceuticals Inc.

Provide Cash Ratio
for Terns Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Terns Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Terns Pharmaceuticals Inc?

What is the current Free Cash Flow
of Terns Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Terns Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Terns Pharmaceuticals Inc

Current Assets 230.2m
Cash & Short-Term Investments 225.3m
Other Current Assets 4.9m
Non-Current Assets 642k
PP&E 587k
Other Non-Current Assets 55k
Current Liabilities 11m
Accounts Payable 1.9m
Accrued Liabilities 8.8m
Other Current Liabilities 320k
Non-Current Liabilities 1.2m
Other Non-Current Liabilities 1.2m
Efficiency

Earnings Waterfall
Terns Pharmaceuticals Inc

Revenue
0 USD
Operating Expenses
-108.2m USD
Operating Income
-108.2m USD
Other Expenses
12.3m USD
Net Income
-95.9m USD

Free Cash Flow Analysis
Terns Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

TERN Profitability Score
Profitability Due Diligence

Terns Pharmaceuticals Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

18/100
Profitability
Score

Terns Pharmaceuticals Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

TERN Solvency Score
Solvency Due Diligence

Terns Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Terns Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TERN Price Targets Summary
Terns Pharmaceuticals Inc

Wall Street analysts forecast TERN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TERN is 19.295 USD with a low forecast of 5.555 USD and a high forecast of 31.5 USD.

Lowest
Price Target
5.555 USD
15% Downside
Average
Price Target
19.295 USD
196% Upside
Highest
Price Target
31.5 USD
383% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for TERN?

Click here to dive deeper.

Dividends

Terns Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for TERN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Terns Pharmaceuticals Inc Logo
Terns Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

572.2m USD

Dividend Yield

0%

Description

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 41 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing a portfolio of small-molecule single-agent and combination therapy candidates to address diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Its lead program, TERN-101, is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR), agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver but only transient FXR activation in the intestine. Its TERN-501 is a thyroid hormone receptor beta (THR-B) agonist with metabolic stability and improved liver distribution. Its TERN-201 is an inhibitor of vascular adhesion protein-1 (VAP-1) that has demonstrated target engagement in clinical trials. Its TERN-601 is its small-molecule Glucagon-Like Peptide-1 Receptor (GLP-1R) agonist program that is intended to be orally administered for NASH and obesity.

Contact

CALIFORNIA
Foster City
1065 East Hillsdale Blvd., Suite 100, Suite 100
+16505255535.0
ternspharma.com

IPO

2021-02-05

Employees

41

Officers

CFO & Treasurer
Dr. Mark Joseph Vignola Ph.D.
CEO & Director
Ms. Amy L. Burroughs M.B.A.
Chief Legal Officer
Ms. Elona Kogan Esq., J.D.
Senior Vice President of Research
Dr. Jeffrey R. Jasper Ph.D.
Chief Medical Officer
Dr. Emil T. Kuriakose M.D.
Chief Business Officer
Ms. Melita Sun Jung
Show More
Chief Development Officer
Mr. Scott Harris
Senior Vice President of Medical Affairs
Ms. Debra Sieminski
VP of Finance & Controller
Mr. David Eric Strauss
Show Less

See Also

Discover More
What is the Intrinsic Value of one TERN stock?

The intrinsic value of one TERN stock under the Base Case scenario is 3.121 USD.

Is TERN stock undervalued or overvalued?

Compared to the current market price of 6.515 USD, Terns Pharmaceuticals Inc is Overvalued by 52%.

Back to Top